Adalimumab, a humanized recombinant antibody directed against soluble and cell-bound tumor necrosis factor-alpha (TNF-α), has increasingly been recognized as a promising agent for treating noninfectious uveitis in adults and children (1–4). Here, TNF is linked to uveitis.